drugset / Trial / NCT03218384

Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency

NCT03218384

Phase 2 Terminated 20 enrolled NYU Langone Health
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to better understand how body levels of iron affect the ability to exercise in patients with heart failure (HF). Heart failure is a condition in which abnormal pumping action of the heart reduces the flow of blood to the body. Patients with heart failure may feel shortness of breath or leg fatigue when they exercise. Iron is an essential nutrient in the diet. In heart failure patients, low body levels of iron might increase shortness of breath and fatigue.

Timeline

Start
2017-09-07
Primary completion
2022-04-04
Completion
2022-04-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferric carboxymaltose Other / unclassified 750 mg Intravenous